SBL
ITCI

Sargent Bickham Lagudis’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sargent Bickham Lagudis’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-197
Closed -$3K – 832
2017
Q3 		$3K Hold
197
– – ﹤0.01% 746
2017
Q2 		$2K Hold
197
– – ﹤0.01% 733
2017
Q1 		$3K Hold
197
– – ﹤0.01% 688
2016
Q4 		$3K Hold
197
– – ﹤0.01% 659
2016
Q3 		$3K Hold
197
– – ﹤0.01% 669
2016
Q2 		$8K Hold
197
– – ﹤0.01% 578
2016
Q1 		$5K Buy
+197
New +$6.57K ﹤0.01% 634

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sargent Bickham Lagudis's ITCI Position: Q4 2017 in Review

Sargent Bickham Lagudis sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2017, closing a stake of 197 shares — an estimated $3K sold.

Sargent Bickham Lagudis first reported a position in ITCI in Q1 2016 and held it in 7 quarters. The position peaked at $8K in Q2 2016. 131 funds tracked by Wall St. Rank hold ITCI as of Q4 2017.

  • Sargent Bickham Lagudis reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2017 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 197 Intra-Cellular Therapies Inc. shares in Q4 2017, an estimated $3K.
  • Sargent Bickham Lagudis first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 7 quarters.
  • Sargent Bickham Lagudis's Intra-Cellular Therapies Inc. position peaked at $8K in Q2 2016.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2017.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2017, filed 13 Sep 2021.